| Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer MM Heck, R Tauber, S Schwaiger, M Retz, C D’Alessandria, T Maurer, ... European urology 75 (6), 920-926, 2019 | 255 | 2019 |
| PET of CXCR4 expression by a 68Ga-labeled highly specific targeted contrast agent E Gourni, O Demmer, M Schottelius, C D'Alessandria, S Schulz, ... Journal of Nuclear Medicine 52 (11), 1803-1810, 2011 | 232 | 2011 |
| Radiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions S Okamoto, A Thieme, J Allmann, C D’Alessandria, T Maurer, M Retz, ... Journal of Nuclear Medicine 58 (3), 445-450, 2017 | 200 | 2017 |
| Systemic Radioligand Therapy with 177Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration … MM Heck, M Retz, C D'Alessandria, I Rauscher, K Scheidhauer, T Maurer, ... The Journal of urology 196 (2), 382-391, 2016 | 199 | 2016 |
| Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA B Feuerecker, R Tauber, K Knorr, M Heck, A Beheshti, C Seidl, ... European urology 79 (3), 343-350, 2021 | 164 | 2021 |
| Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study A Gafita, J Calais, TR Grogan, B Hadaschik, H Wang, M Weber, S Sandhu, ... The Lancet Oncology 22 (8), 1115-1125, 2021 | 147 | 2021 |
| 99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques A Annovazzi, E Bonanno, M Arca, C D’Alessandria, A Marcoccia, ... European journal of nuclear medicine and molecular imaging 33, 117-126, 2006 | 106 | 2006 |
| Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study ME Autenrieth, C Seidl, F Bruchertseifer, T Horn, F Kurtz, B Feuerecker, ... European Journal of Nuclear Medicine and Molecular Imaging 45, 1364-1371, 2018 | 74 | 2018 |
| The effect of total tumor volume on the biologically effective dose to tumor and kidneys for 177Lu-labeled PSMA peptides NJ Begum, A Thieme, N Eberhardt, R Tauber, C D’Alessandria, AJ Beer, ... Journal of Nuclear Medicine 59 (6), 929-933, 2018 | 70 | 2018 |
| 99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study A Signore, A Annovazzi, R Barone, E Bonanno, C D’Alessandria, ... Journal of Nuclear Medicine 45 (10), 1647-1652, 2004 | 67 | 2004 |
| Nuclear medicine imaging of inflammatory/infective disorders of the abdomen A Annovazzi, B Bagni, L Burroni, C D'Alessandria, A Signore Nuclear medicine communications 26 (7), 657-664, 2005 | 63 | 2005 |
| Can we produce an image of bacteria with radiopharmaceuticals? A Signore, C D’Alessandria, E Lazzeri, R Dierckx European journal of nuclear medicine and molecular imaging 35, 1051-1055, 2008 | 56 | 2008 |
| Immuno-PET imaging of engineered human T cells in tumors S Mall, N Yusufi, R Wagner, R Klar, H Bianchi, K Steiger, M Straub, ... Cancer Research 76 (14), 4113-4123, 2016 | 53 | 2016 |
| Modeling and predicting tumor response in radioligand therapy P Kletting, A Thieme, N Eberhardt, A Rinscheid, C D’Alessandria, ... Journal of nuclear medicine 60 (1), 65-70, 2019 | 49 | 2019 |
| Selective imaging of the angiogenic relevant integrins α5β1 and αvβ3 S Neubauer, F Rechenmacher, AJ Beer, F Curnis, K Pohle, ... Angewandte Chemie International Edition 52 (44), 11656-11659, 2013 | 48 | 2013 |
| Use of a 99mTc labeled anti-TNFalpha monoclonal antibody in Crohn’s disease: in vitro and in vivo studies C D'alessandria, G Malviya, A Viscido, A Aratari, F Maccioni, A Amato, ... QJ Nucl Med Mol Imaging 51 (4), 334-342, 2007 | 46* | 2007 |
| Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3 A Bartolazzi, C D'Alessandria, MG Parisella, A Signore, F Del Prete, ... PLoS One 3 (11), e3768, 2008 | 42 | 2008 |
| Early prostate-specific antigen changes and clinical outcome after 177Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer A Gafita, MM Heck, I Rauscher, R Tauber, L Cala, C Franz, ... Journal of Nuclear Medicine 61 (10), 1476-1483, 2020 | 41 | 2020 |
| Preclinical Evaluation of the Hsp70 Peptide Tracer TPP-PEG24-DFO[89Zr] for Tumor-Specific PET/CT Imaging S Stangl, L Tei, F De Rose, S Reder, J Martinelli, W Sievert, M Shevtsov, ... Cancer Research 78 (21), 6268-6281, 2018 | 40 | 2018 |
| Synthesis and Optimization of the Labeling Procedure of 99mTc-Hynic-Interleukin-2 for In vivo Imaging of Activated T lymphocytes C D’Alessandria, V Di Gialleonardo, M Chianelli, SJ Mather, EFJ de Vries, ... Molecular imaging and biology 12, 539-546, 2010 | 40 | 2010 |
